Tocilizumab for rheumatoid and juvenile idiopathic arthritis

The Lancet

Volumn 371, Issue 9617, 2008, Pages 961-963

  Bongartz, Tim ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PATIENT CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT RESPONSE;

EID: 40749155784     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60428-6     Document Type: Note

References (20)

1. Keystone E., Kavanaugh A., Sharp J., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
2. Maini R., St Clair E., Breedveld F., et al., for the ATTRACT study group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
3. Klareskog L., van der Heijde D., de Jager J., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
4. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
5. Cohen S., Hurd E., Cush J., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 614-624
6. Kremer J., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
7. Lovell D., Giannini E., Reiff A., et al., for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342 (2000) 763-769
8. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
9. Smolen J., Beaulieu A., Rubbert-Roth A., et al., for the OPTION investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008) 987-997
10. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008) 998-1006
11. van der Kooij S., de Vries-Bouwstra J., Goekoop-Ruiterman Y., et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66 (2007) 1356-1362
12. Giannini E., Brewer E., Kuzmina N., et al., for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 326 (1992) 1043-1049
13. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48 (2003) 1093-1101
14. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (2007) 1162-1167
15. Maradit-Kremers H., Crowson C., Nicola P., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52 (2005) 402-411
16. Gonzalez A., Kremers H.M., Crowson C., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 67 (2008) 64-69
17. Wilson P., D'Agostino R., Levy D., Belanger A., Silbershatz H., and Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
18. Chung C., Oeser A., Avalos I., et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 8 (2006) R186
19. Dixon W., Watson K., Lunt M., et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56 (2007) 2905-2912
20. Seriolo B., Paolino S., Sulli A., Fasciolo D., and Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069 (2006) 414-419